Years after Pfizer passed on a buyout option, AM-Pharma finds a new partner for its kidney drug

Years after Pfizer passed on a buyout option, AM-Pharma finds a new partner for its kidney drug

Source: 
Endpoints
snippet: 

A couple of years ago, Pfizer passed on an option to buy out AM-Pharma and its recombinant human alkaline phosphatase for kidney failure on the heels of some mixed Phase II data. Now, the program has attracted a new partner — and an approval could mean a big payout for AM-Pharma.